Search clinical trials for: Alogliptin and insulin

Total 272067 results

Sanofi

Terminated

Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Diabetes Mellitus, Type 2

Brazil
Sanofi

Completed

Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study (GLANS)

Diabetes Mellitus, Type 1

Bahrain, Kuwait, Qatar, United Arab Emirates
Sanofi

Completed

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Diabetes Mellitus

China
Sanofi

Completed

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine (GEMELLI1)

Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus

Hungary, Russian Federation, Germany, Poland, Japan, United States, Finland
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Completed

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Type 2 Diabetic Patients | Insufficient Metabolic Control | OAD Treatment

Germany
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Type 2 Diabetes

Canada
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Mexico, Netherlands, Russian Federation, India, Belgium, Japan, Romania, Italy
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1

United States, Brazil
Nastech Pharmaceutical Company, Inc.

Completed

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

Diabetes Mellitus

United States
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, Canada
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Tonghua Dongbao Pharmaceutical Co.,Ltd

Completed

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

Diabetes

China
Sanofi

Completed

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Terminated

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (iDEAt2)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Israel, Taiwan, Malaysia, Hungary, Turkey, Morocco, Germany, South Africa, Portugal, Lebanon, Italy, Brazil, Croatia, Egypt, Spain, Russian Federation, Greece, Argentina, Korea, Republic of, Poland, Serbia
Novo Nordisk A/S

Completed

NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Indonesia
Novo Nordisk A/S

Completed

Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
University of Aarhus
Novo Nordisk A/S; The Danish Diabetes Association; The Institute of Experimental...

Completed

Basal Insulins - Pharmacodynamics

Diabetes

Denmark
Sanofi

Completed

Insulin Glulisine in Diabetes Mellitus, Type 2 (GINGER)

Diabetes Mellitus, Type 2

France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment

Diabetes Mellitus, Type 2 | Diabetes

Spain
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Kirsten Nørgaard

Unknown

Fast-Acting Insulin Aspart and Insulin Pump Settings

Type 1 Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
University of Minnesota

Completed

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Cystic Fibrosis

United States
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus (PUMP)

Diabetes Mellitus, Type 1

France, Australia, Spain, Sweden, United States, Austria, Hungary, Israel, Italy, United Kingdom, Korea, Republic of, Netherlands
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Novo Nordisk A/S

Completed

Efficacy and Safety of Levemir® Used as Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Slovakia
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
Novo Nordisk A/S

Completed

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Medical University of Graz
European Commission

Completed

Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes

Type 1 Diabetes

Austria
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
Novo Nordisk A/S

Terminated

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Hadassah Medical Organization

Unknown

Insulin Loaded Orally Dissolved Films (Insulin-ODF)

Healthy Volunteers
Baylor College of Medicine

Completed

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients (GIH)

Hyperglycemia | Diabetes Mellitus

United States
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) (ONWARDS 6)

Diabetes Mellitus, Type 1

United States, India, Italy, Russian Federation, United Kingdom, Canada, Netherlands, Austria, Japan, Spain, Germany, Turkey

3

Subscribe